I期临床试验中基于药代动力学的剂量递增。评论与拟议指南。欧洲癌症研究与治疗组织药代动力学与代谢小组。 - Suppr

Suppr

超能文献

Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. EORTC Pharmacokinetics and Metabolism Group.

出版信息

Eur J Cancer Clin Oncol. 1987 Jul;23(7):1083-7. doi: 10.1016/0277-5379(87)90365-8.

DOI:10.1016/0277-5379(87)90365-8

PMID:3665996

Abstract

摘要

相似文献

Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. EORTC Pharmacokinetics and Metabolism Group.I期临床试验中基于药代动力学的剂量递增。评论与拟议指南。欧洲癌症研究与治疗组织药代动力学与代谢小组。

Eur J Cancer Clin Oncol. 1987 Jul;23(7):1083-7. doi: 10.1016/0277-5379(87)90365-8.

[Pharmacokinetically guided dose-escalation (PGDE) strategy].[药代动力学指导的剂量递增（PGDE）策略]

Gan To Kagaku Ryoho. 2000 Jul;27(7):1069-74.

The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies.药代动力学指导的剂量递增策略在I期临床试验中的影响：批判性评估及对未来研究的建议。

Ann Oncol. 1992 May;3(5):339-47. doi: 10.1093/oxfordjournals.annonc.a058203.

EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee.

Eur J Cancer Clin Oncol. 1985 Sep;21(9):1005-7. doi: 10.1016/0277-5379(85)90282-2.

Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.蒽吡唑CI-941的I期试验：药代动力学指导剂量递增的前瞻性评估。

Eur J Cancer. 1992;28(2-3):463-9. doi: 10.1016/s0959-8049(05)80077-2.

Statistical requirements of phase I studies.

Onkologie. 1990 Apr;13(2):90-5. doi: 10.1159/000216733.

Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.蒽吡唑 CI-941 的临床药代动力学：影响药代动力学指导的剂量递增方案实施的因素

Cancer Res. 1992 Feb 1;52(3):603-9.

[A combination phase I/II study--dose escalation plan].一项I/II期联合研究——剂量递增计划

Gan To Kagaku Ryoho. 2000 Dec;27(14):2267-74.

Pharmacokinetics and early clinical studies of selected new drugs.选定新药的药代动力学及早期临床研究

Cancer Surv. 1993;17:371-96.

Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.4'-碘-4'-脱氧阿霉素的药理学与临床毒性：一期试验中成功将药代动力学应用于剂量递增的实例

J Natl Cancer Inst. 1990 Mar 21;82(6):469-77. doi: 10.1093/jnci/82.6.469.

引用本文的文献

Comparisons of Methods for Mucus Sampling and Mucin Semi-Quantification on Barramundi (Lates calcarifer) and Atlantic Salmon (Salmo salar) Epithelial Sites.尖吻鲈（尖吻鲈属）和大西洋鲑（大西洋鲑属）上皮部位黏液采样及黏蛋白半定量方法的比较

Mar Biotechnol (NY). 2025 Sep 24;27(5):140. doi: 10.1007/s10126-025-10515-z.

The Valley of Death in anticancer drug development: a reassessment.抗癌药物研发中的“死亡谷”：再评估。

Trends Pharmacol Sci. 2012 Apr;33(4):173-80. doi: 10.1016/j.tips.2012.02.001. Epub 2012 Mar 10.

Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTG.

Cancer Chemother Pharmacol. 1993;31(5):395-400. doi: 10.1007/BF00686154.

Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations.

Cancer Chemother Pharmacol. 1993;32(6):411-8. doi: 10.1007/BF00685883.

Limited-sampling models for anticancer agents.抗癌药物的有限采样模型。

J Cancer Res Clin Oncol. 1994;120(7):427-33. doi: 10.1007/BF01240143.

Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.用于生物还原药物替拉扎明及其主要代谢物的灵敏固相萃取和高效液相色谱分析方法的开发与验证，该方法用于小鼠和人血浆中替拉扎明的药代动力学指导剂量递增研究。

Cancer Chemother Pharmacol. 1995;36(3):266-70. doi: 10.1007/BF00685859.

Concentration-controlled trials. What does the future hold?浓度控制试验。未来会怎样？

Clin Pharmacokinet. 1995 Feb;28(2):93-9. doi: 10.2165/00003088-199528020-00001.

Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

Cancer Chemother Pharmacol. 1995;36(6):524-9. doi: 10.1007/BF00685803.

When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?在估算人体药物的药代动力学参数时，何时可以安全地忽略输注期？

Cancer Chemother Pharmacol. 1988;22(2):95-103. doi: 10.1007/BF00257304.

The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.蒽吡唑类抗癌药物CI-941在小鼠体内的药代动力学和毒性：患者合理剂量递增指南

Cancer Chemother Pharmacol. 1989;23(1):8-14. doi: 10.1007/BF00258450.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验